Immune activation, which is characteristic of both tuberculosis (TB) and human immunodeficiency virus (HIV) infection, is associated with impaired drug metabolism. We tested the hypothesis that elevated levels of systemic immune activation among adults with HIV/TB initiating antiretroviral therapy (ART) would be associated with impaired clearance of isoniazid.
METHODS
We conducted a prospective observational study of isoniazid pharmacokinetics (PK) and systemic immune activation prior to and 1 month after ART initiation. Nonlinear mixed effects analysis was performed to measure the covariate effect of immune activation on isoniazid clearance in a model that also included N-acetyltransferase-2 (NAT-2) genotype and interoccasional variability on clearance (thereby analyzing the PK data before and after ART initiation in a single model).
RESULTS
We enrolled 40 patients in the PK visit prior to ART, and 24 patients returned for the second visit a median of 33 days after initiating antiretroviral therapy. The isoniazid concentration data were best described by a two-compartment model with first-order elimination. After accounting for NAT-2 genotype, increasing levels of CD38 and HLA-DR expression on CD8+ T cells (CD38 + DR + CD8 + ) were associated with decreasing isoniazid clearance.
CONCLUSION Introduction
Treatment with isoniazid is associated with elevated liver enzymes in up to 20% of tuberculosis (TB) patients, with overt hepatotoxicity in up to 1% of those taking the drug [1] [2] [3] . Hepatic injury due to isoniazid is believed to result from toxic hydrazine metabolites that accumulate when there is impairment of the acetylation pathway, although more recent work has re-visited the possibility of immunemediated injury from isoniazid itself [4] . The key drug metabolizing enzyme in this pathway is N-acetyltransferase-2 (NAT-2). Slow isoniazid acetylators, those who carry no rapid NAT-2 alleles, have a greater area under the isoniazid concentration-vs.-time curve during the 24-hour dosing interval (AUC 0-24 ) than intermediate or rapid acetylators (with one or two rapid alleles, respectively) [5, 6] . A metaanalysis of 14 clinical studies demonstrated a nearly five-fold increased risk of hepatotoxicity in NAT-2 slow acetylators compared to others [7] . In a randomized trial of a genotypebased dosing algorithm for isoniazid during active TB therapy, hepatocellular injury was reduced among slow acetylators treated with reduced isoniazid doses, with no difference in microbiologic outcomes [8] .
Human immunodeficiency virus (HIV) infection has been associated with an increased risk for isoniazid-associated hepatotoxicity, raising the possibility that immune dysregulation itself could contribute to increased drug toxicity through undefined pathways [9] [10] [11] [12] . Patients infected with HIV have chronic immune activation and cytokine dysregulation, characterized by increased CD38 and HLA-DR expression on CD8+ T cells (CD38 + DR + CD8 + ) and an increase in levels of circulating proinflammatory cytokines such as interleukin-6 (IL-6), C-reactive protein (CRP) and tumour necrosis factor-α (TNF-α) [13] [14] [15] . The degree of immune activation is often higher in patients with more advanced HIV disease [16] , and levels may increase further during immune restoration on antiretroviral therapy (ART), particularly in patients with opportunistic infections [17] . Immune activation and proinflammatory cytokines are known to regulate the expression and activity of some phase I xenobiotic metabolic enzymes and drug transporters [18, 19] . Patients with high levels of inflammation and immune activation due to other causes, such as bacterial sepsis or acute viral infections, demonstrate impaired drug metabolizing capacity [20, 21] . Furthermore, HIV-infected individuals with rapid acetylator NAT-2 genotypes have demonstrated slow acetylation phenotypes based on metabolism of caffeine, possibly implicating immune activation in drug pharmacokinetics (PK) [22, 23] .
Consistent with this, among 235 South African pulmonary TB patients, HIV infection was found to decrease isoniazid systemic clearance (CL) by 17% in a population PK model [24] . We tested the overall hypothesis that increasing levels of systemic immune activation among TB patients coinfected with HIV, measured primarily as the percentage of CD8+ T cells expressing CD38 and HLA-DR (%CD38 + DR + CD8 + ), would be associated with impaired isoniazid CL.
Methods

Ethics
Written informed consent was obtained from all patients and the study was approved by the institutional review boards of Ministry of Health of Botswana and the University of Pennsylvania.
Study design
We conducted a prospective study of isoniazid PK in HIV/TB patients at 22 public clinics and at Princess Marina Hospital in Gaborone, Botswana.
Study population
HIV-infected adults (aged 21 years and older) were eligible for enrolment if they were ART-naïve citizens of Botswana newly diagnosed with pulmonary TB. Patients must have been initiated on a standard first-line TB treatment regimen, following WHO guidelines for weight-based dosing bands [25] . The diagnosis of pulmonary TB must have been established by either a positive sputum smear, a positive GeneXpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA), or the presence of WHO criteria for smear-negative pulmonary TB. Exclusion criteria included pregnancy, renal insufficiency (defined as a creatinine clearance <50 ml min À1 ), and hepatic dysfunction (defined as either an alanine transaminase or aspartate transaminase >3 times the upper limit of normal).
Data collection
The study procedures consisted of two study visits, with each visit conducted at the Infectious Disease Care Clinic at Princess Marina Hospital. The first study visit occurred between 5 and 28 days after the initiation of anti-TB therapy, corresponding to steady-state conditions. All participants were eligible to return for a second PK visit during the intermittent phase of anti-TB therapy, provided that ART had also been initiated. The procedures for each study visit were identical. After an overnight fast, the anti-TB drugs were directly administered to the participant. Blood samples (10 ml) were drawn at 0, 0. Aldrich), as previously described [17] . Cells were incubated overnight at 37°C, 5% CO 2 . One million PBMCs were then stained with LIVE/DEAD fixable aqua stain (Life Technologies) for dead cell exclusion followed by staining with anti-CD3-BV570 (Biolegend), anti-CD8-QD605 (Life Technologies), anti-CD4-QD705 (Life Technologies), anti-CD38-PE-Cy7 (Biolegend), and anti-HLA-DR-BV786 (Biolegend). Stained cells were acquired on an LSR II (BD Biosciences). Flow cytometric data were analyzed using FlowJo Version 9.8.2 (TreeStar).
Serum isoniazid concentrations. Cryopreserved serum samples for each PK time point were shipped to the Gumbo Laboratory at the Baylor Research Institute (Dallas, TX, USA). Stable-isotope dilution liquid chromatographyelectrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) was used to determine isoniazid concentrations in serum samples [27] . Isoniazid and the stable isotope labelled isonicotinoyl-d4-hydrazide (Isoniazid-d4) were purchased from Sigma (St. Louis, MO, USA) and CDN Isotopes (Quebec, Canada). Calibrators, controls, and internal standards (isoniazid-d4) were included in each analytical run for quantitation. Stock solutions of each standard and internal standard were prepared in 80:20 methanol:water or dimethyl sulfoxide at a concentration of 1 mg ml À1 and stored at -20°C. A six-point calibration curve was prepared by diluting the stock solution in water containing 0.2% formic acid. Quality control samples were prepared by spiking human serum with stock standards at two levels of controls (0.4 mg l À1 and 4.0 mg l À1 ). The correlation coefficient was 0.9986, with 4.1% intraday precision (n = 14) and 22.5% interday precision (n = 6), and a lower limit of quantification of 0.16 mg l À1 .
Preparation of serum comprised of the addition of 10 μL of calibrator, quality controls, or sample to 190 μL 0.2% formic acid in water followed by vortex. The serum was then diluted further by performing another 1:10 dilution in 0.2% formic acid in water containing 4 μg ml À1 labeled-isotope internal standards, followed by vortex and centrifugation at 1.5 × g for 5 min to remove cellular debris. Chromatographic separation was achieved on an Acquity UPLC HSS T3 1.8 μm 50 × 2.1 mm analytical column (Waters) maintained at 30°C at a flow of 0.2 ml min À1 with a binary gradient. Solvents for UPLC were: (A) water containing 0.1% formic acid; and (B) methanol containing 0.1% formic acid. The initial gradient condition was 5% B for the first 1.5 min and was increased in a linear fashion to 100% B at 1.8 min and held constant for 1.5 min. At 3.5 min, the flow was reset to initial conditions for 4.5 min that gave a total analysis time of 9 min. The flow from the column was delivered to the Turbulon ion source from the period of 1-5 min. The compounds were detected by MS/MS using positive ESI, complete LC, Turbulon source, mass transitions, and optimized collision-induced dissociation conditions. Sample injection and chromatographic separation were performed by a Shimadzu Nexera UPLC interfaced with a Sciex 5500QTRAP mass spectrometer. All data were collected and analyzed using Analyst 6.1.
Whole exome sequencing. Blood samples were shipped to the Gumbo laboratory at the Baylor Research Institute for whole exome sequencing. DNA from whole blood samples was extracted using the QIAamp DNA Blood mini kit (QIAGEN) following the manufacturer's protocol. The DNA was first sonicated using Covaris S220 platform to generate genomic fragments between 300 and 400 bp. Sequencing libraries were generated using KAPA Biosystem library preparation kits (KK8232). Each sample was ligated with custom designed Illumina-compatible adaptors with unique six-base barcodes following the kit manufacturer's protocol. In the next step, 300-500 ng of library from each sample was hybridized with SeqCap EZ Human Exome Library v3.0 (Product # 06 465 684 001, NimbleGen). Finally, five enriched libraries were pooled on a lane and sequenced using a paired-end 100 bp (PE100) protocol on HiSeq 2500 platform (Illumina). The sequence reads were aligned to the human genome (HG19) using BWA-MEM, with local realignment performed using the Genome Analysis Toolkit (GATKv2). We used SNP & Variation suite (SVS) of Golden Helix (version 7.6.8 win64, Golden Helix, Inc., Bozeman, MT, www.goldenhelix.com) for genetic analysis.
NAT-2 genotype. Individuals with any combinations of the following NAT-2 alleles: 2*4, 2*11, 2*12 and 2*13, were classified rapid acetylators, while those with both combination of these alleles: 2*5, 2*6, 2*7 and 2*14, were considered slow acetylators in accordance with existing literature [28] . Patients who possessed one allele from the former group and another from the later were classified as intermediate acetylators. Table S1 , and the positions in the NAT-2 gene for identification of alleles are in S2.
Statistical analysis
Nonlinear mixed effects modelling was performed to estimate the PK parameters [29] . Model development used first-order conditional estimation (FOCE) in Phoenix NLME 1.3 (Certara) to provide estimates of the typical values for population PK parameters, between-subject variability (BSV), and residual variability [30] . For nested models, a reduction in the objective function value (OFV) >3.84 for a difference of one degree of freedom was considered statistically significant (P < 0.05), assuming a chi-squared distribution. Goodnessof-fit was examined visually with plots of observed vs. population predicted concentration, observed vs. individual predicted concentrations, individual weighted residuals vs. individual predicted concentrations, and conditional weighted residuals vs. time. Plasma concentration-time data were fitted to one-and two-compartment models with first-order elimination. Between-subject variability was evaluated with an exponential variability model with mean of zero and variance ω 2 .
Inclusion of BSV was evaluated individually for each PK parameter, and inclusion in the model was based on reduction in the OFV corresponding to P < 0.05. Additive, proportional and combined residual error models were tested to describe residual unexplained variability. Interoccasional variability was modelled with a mean of zero and variance κ 2 .
The final model was selected based on biological plausibility, goodness-of-fit as evidenced by visual examination of diagnostic plots, and statistical criteria [31] . Visual predictive checks were used to evaluate the performance of candidate and final models for isoniazid PK, by simulation of 500 datasets. The distribution (median, 10 th and 90 th percentiles) of the simulated concentrations vs. time were compared with the distribution of the observed values in the original dataset. Differences and overlap of the simulated and original distributions indicated the accuracy of the identified model [32] . We reasoned that any covariate that explained at least 25% of the observed variability in isoniazid CL would reach the threshold of clinical significance, based on the bioequivalence standard that a compound would be considered nonequivalent if any PK parameter is < 80% or >125% of the comparator. Assuming a 1:1 distribution between slow and intermediate/rapid acetylators, we estimated that we would have 86% power to detect this contribution with a total of 40 participants enrolled in the study.
Results
We screened 61 patients with HIV/TB in Gaborone, Botswana, of whom 40 signed informed consent and were enrolled in the study. The demographic and clinical characteristics of the participants are shown in Table 1 . At the time of the first study visit, the median duration of anti-TB therapy was 20 days (range 7-65 days), and no patients were receiving ART. The median CD4+ T cell count was 238 × 10 6 cells l Twenty-four patients returned for the second PK study visit after the initiation of ART. The patients who returned for the second visit were not statistically different from those who did not return (Table 1) . At the time of the second visit, the median duration of anti-TB therapy was 74 days (range 33-118 days), and participants had been receiving ART for a median of 33 days (range 5-44 days). The ART regimen for all patients was tenofovir/emtricitabine/efavirenz. At the time of the second visit, the HIV viral load was observed to have decreased in all but one participant compared to the first visit, and the median CD4+ T cell count increased to 308 × 10 6 cells l Figure 1 . The isoniazid concentration data were best described by a two-compartment model with first-order elimination, BSV on the central volume (V) and CL, and a combined additive/proportional residual error model. Fit of the concentrations during the absorptive phase was improved with the use of a time-lag absorption model and thus completed the formation of the base model (without covariate effects). A box-plot of BSV against NAT-2 genotype demonstrated a strong covariate effect (Figure 2A ), which indicated that isoniazid CL was lower than predicted among patients with a slow NAT-2 genotype, and greater than predicted among patients with a rapid NAT-2 genotype. The addition of NAT-2 genotype as a covariate on isoniazid CL led to a significant reduction of 13.73 in the objective function value (P = 0.001), with a reduction in BSV in isoniazid CL (representing unexplained variability) from 45.9% to 32.0%. Covariate relationships that were examined, but not retained in the model, included creatinine clearance, sex, and weight as covariates on V, CL, the volume of the peripheral compartment, and intercompartmental clearance.
To examine the effect of immune activation on variability in isoniazid CL, we introduced interoccasional variability (IOV) on CL into the population PK model, which included the covariate effect of NAT-2 genotype on CL, and BSV on CL, V, and Tlag ( Table 2 ). As shown in Figure 2B, Figure  S1 . The visual predictive checks for the final model are shown in S2, overall and stratified by NAT-2 genotype. The distributions of individual predicted CL and AUC 0-inf , based on the model that included the covariate effects of NAT-2 and %CD38 + DR + CD8 + on CL, are shown in Figure 3A (CL) and 3B (AUC). Following the initiation of ART, individual predicted isoniazid CL increased among three of five slow acetylators, five of nine intermediate acetylators and six of seven rapid acetylators. There were no episodes of clinical hepatotoxicity among the study subjects during the observation period.
Discussion
In this study, we hypothesized that levels of systemic immune activation, as defined by the percent of circulating CD8 + T cells coexpressing CD38 and HLA-DR, would contribute to variability in isoniazid CL among HIV-infected, ART-naive patients being treated for pulmonary TB. We rejected the null hypothesis by finding a significant effect of %CD38 + DR + CD8 + on isoniazid CL in a two-compartment model that also included the effect of NAT-2 genotype on CL. The direction of the relationship moved in the direction we hypothesized, with falling levels of immune activation associated with increasing isoniazid CL. This is the first study to demonstrate an association between immune activation and isoniazid CL, but the results Median plasma neopterin concentration (IQR), ng ml Isoniazid PK in HIV/TB are consistent with previous reports from other settings. Although our study was not powered to examine clinical hepatotoxicity endpoints, our findings are consistent with observations of high levels of immune activation and high rates of hepatocellular dysfunction early during TB therapy among HIV-infected, ART-naïve patients [9] [10] [11] [12] . Furthermore, impaired drug metabolism activity among patients with heightened inflammatory activity has been described for several decades across a broad range of clinical states, including influenza, sepsis syndrome and post-bone marrow transplantation [18] [19] [20] [21] [22] [23] . Much of this work has focused on cytochrome p450 substrate drugs, and the mechanisms whereby inflammation suppresses drug metabolizing activity remain uncertain. In vitro studies with hepatocyte cell culture demonstrate that coculture of hepatocytes with proinflammatory cytokines downregulates the expression of cytochrome P450 isoenzymes, in particular CYP3A4 [19] . Moreover, there has been a single report of the downregulation of NAT-1 expression in human cholangiocarcinoma cells after treatment with proinflammatory cytokines [33] . Based on our findings, additional work to understand NAT-2 regulation, isoniazid PK and TB treatment outcomes are warranted. The effect of proinflammatory cytokines on the expression and activity of other key enzymes involved in isoniazid metabolism, including CYP2E1, should also be investigated [34] . Earlier studies conducted in HIV-infected patients have observed discordance between NAT-2 genotype and phenotype in advanced HIV disease, with rapid genotype demonstrating a slow phenotype [22, 23] . In contrast to these earlier studies, which used caffeine probes to assess NAT-2 activity, we found that NAT-2 genotype contributed to variability in isoniazid metabolism to an extent similar to previous reports from HIV-uninfected populations. This discrepancy could be due to a general limitation of the caffeine probe to predict isoniazid CL, specific differences in the study populations, or the analysis methods. In our study, the contribution of immune activation added to the effect of NAT-2 genotype, and therefore the highest levels of isoniazid exposure were found among slow NAT-2 genotype patients with high levels of immune activation. In contrast, CD4+ T cell counts did not exert a significant covariate effect on isoniazid clearance, suggesting that immune activation rather than immune suppression drives the variability in NAT-2 activity. Further studies are needed to evaluate the contribution of HIV-associated immune activation to the risk of hepatotoxicity, in the context of CYP2E1 and glutathione-S-transferase genotype and activity, which are also known to contribute to this risk through production of toxic hydrazine metabolites [35] .
Recent work has demonstrated that isoniazid may bind covalently to hepatocytes, and this cell surface complex is subsequently recognized as a hapten by the innate immune system, triggering immune response and hepatocellular injury [36] . Our work suggests an additional pathway relating immune response and isoniazid hepatotoxicity, in that high levels of immune activation could directly or indirectly inhibit NAT-2 activity, leading to accumulation of isoniazid Isoniazid PK in HIV/TB or its hydrazine metabolites. Impaired NAT-2 activity at the start of anti-TB therapy, when levels of immune activation are greatest, could explain the higher rates of adverse events noted by clinicians in patients with acquired immunodeficiency syndrome, particularly early during TB treatment [3] . This work provides additional support for individualized isoniazid dosing to achieve target serum concentrations [27] , given the potent combined effects of NAT-2 genotype and immune activation on isoniazid PK that were observed in this population.
This study had a number of important limitations. First, this intensive PK study was not powered to study clinical hepatotoxicity events. Nonetheless, the present findings support future studies aiming to assess the relationship between immune activation, isoniazid PK, and clinical outcomes. In particular, examining the hypothesized association in hospitalized, critically ill patients with HIV/TB is of interest as these individuals are likely to have very high levels of immune activation and, as suggested by our data, plausibly could have severely impaired isoniazid CL. In addition, we did not evaluate NAT-2 gene expression directly, and other explanations for the observed associations are possible (such as unmeasured confounding by a comorbid condition or a coadministered medication). Although baseline creatinine clearance was not related to isoniazid clearance, we did not measure changes in creatinine clearance between study visits, which was an additional limitation. Strengths of the study include the novel evaluation of immunologic measures in a nonlinear mixed effects modelling approach, underpinned by a proposed mechanistic relationship, and the repeated measures design to include the effects of interoccasional variability on isoniazid PK.
In summary, we present the novel finding of increasing exposure to isoniazid among HIV/TB patients with increasing levels of immune activation. Future efforts should characterize the time course of this relationship, define the specific mediators of the effect, and explore the potential relationship between isoniazid accumulation, immune response and the risk of hepatotoxicity. Additional relationships between immune activation and drug metabolism or transporter activity relevant to TB therapies should be investigated. BSV, between-subject variability; CL, clearance; IOV, interoccasional variability; NAT2, N-acetyltransferase-2; PK, pharmacokinetics; Q, intercompartmental clearance; RSE, relative standard error;V, Volume of distribution of central compartment; V2, Volume of distribution of peripheral compartment
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